Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?

Journal of Hepatology

Volumn 62, Issue 3, 2015, Pages 751-752

  Carrascosa, Miguel F ^a   Salcines Caviedes, José R ^a   Lucena, M Isabel ^b   Andrade, Raul J ^b  

^a HOSPITAL DE LAREDO   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; CREATINE KINASE; FUROSEMIDE; METFORMIN; OMEPRAZOLE; PHENOBARBITAL; RAMIPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE LIVER FAILURE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DROWSINESS; DRUG DOSE ESCALATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EOSINOPHIL; FATIGUE; FEMALE; FLAPPING TREMOR; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS; HUMAN; IDIOSYNCRATIC HEPATOTOXICIT; INFLAMMATORY INFILTRATE; JAUNDICE; LETTER; LIPID METABOLISM; LIVER BIOPSY; LIVER TOXICITY; PRIORITY JOURNAL; SOMNOLENCE; T LYMPHOCYTE; URINE COLOR; VERY ELDERLY; VOMITING; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; LIVER; PATHOLOGY;

AGED, 80 AND OVER; ATORVASTATIN CALCIUM; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LIVER FAILURE, ACUTE;

EID: 84923029332     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.11.019     Document Type: Letter

References (9)

1. C. Lammert, S. Einarsson, C. Saha, A. Niklasson, E. Bjornsson, and N. Chalasani Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals Hepatology 47 2008 2003 2009
2. C. Lammert, E. Bjornsson, A. Niklasson, and N. Chalasani Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events Hepatology 51 2010 615 620
3. H.S. Malhotra, and K.L. Goa Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia Drugs 61 2001 1835 1881
4. E. Björnsson, E. Jacobsen, and E. Kalaitzakis Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing J Hepatol 56 2012 374 380
5. T. Bader Liver tests are irrelevant when prescribing statins Lancet 376 2010 1882 1883
6. M.W. Russo, J.H. Hoofnagle, J. Gu, R.J. Fontana, H. Barnhart, and D.E. Kleiner Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network Hepatology 60 2014 679 686
7. E.V. Perdices, I. Medina, S. Hernando, A. Ortega, F. Martín-Ocaña, and J.M. Navarro Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry Rev Esp Enferm Dig 106 2014 246 254
8. E.S. Björnsson, O.M. Bergmann, H.K. Björnsson, R.B. Kvaran, and S. Olafsson Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland Gastroenterology 144 2013 1419 1425
9. M. Chen, J. Borlak, and W. Tong High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury Hepatology 58 2013 388 396